Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(10):712; doi:10.1093/jnci/97.10.712
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Zielinski, S. L.
Right arrow Articles by Travis, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Zielinski, S. L.
Right arrow Articles by Travis, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

In Brief

Sarah L. Zielinski, Kate Travis

The first 10% of the full text of this article appears below.

Revised Bethesda Guidelines Identify Patients at Risk for HNPCC

The revised Bethesda Guidelines for selecting individuals for genetic testing for hereditary nonpolyposis colorectal cancer (HNPCC) are effective for identifying patients at risk for the disease, according to a new study.

The revised Bethesda Guidelines for HNPCC made recommendations on which patients should receive genetic testing . . . [Full Text of this Article]

Randomized Trial of Gefitinib for Advanced Lung Cancer Closed Early

Gene Copy Number May Be Associated With Response to EGFR Inhibitors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?